Table 2 Characteristics of patients with indolent lymphoma
From: Synchronous multiple primary tumors in patients with malignant lymphoma: a retrospective study
| Â | High tumor burden indolent lymphoma (n = 12) | Low tumor burden indolent lymphoma (n=27) | P value |
|---|---|---|---|
Initial treatment for lymhpoma | Â | Â | <0.001 |
 Rituximab | 2 (16.7%) | 0 |  |
 Rituximab+chemothrapy | 7 (58.3%) | 3 (11.1%) |  |
 Radiotherapy | 2 (16.7%) | 2 (7.4%) |  |
 Eradication of H.pylori | 0 | 3 (11.1%) |  |
 Watch and wait | 1 (8.3%) | 19 (70.4%) |  |
Treatment for solid tumor | Â | Â | 0.71 |
 Surgery ± chemotherapy | 9 (75.0%) | 13 (48.1%) |  |
 Endocope | 2 (16.7%) | 8 (29.6%) |  |
 Radiotherapy ± chemotherapy | 1 (8.3%) | 3 (11.1%) |  |
 Chemotherapy | 0 | 2 (7.4%) |  |
 Cystoscope | 0 | 1 (3.7%) |  |
Treatment sequence | Â | Â | 0.002 |
 Lymphoma first | 6 (50.0%) | 1 (3.7%) |  |
 Solid tumor first | 6 (50.0%) | 26 (96.3%) |  |